ABSTRACT Introduction: Immunotherapy led to increased survival in advanced non-small cell lung cancer; however, it has also increased treatment costs. In this study, real-world data was used to evaluate the average cost of treatment of patients with lung cancer. Material and Methods: This is a retrospective study that extracted patient-level...
ABSTRACT Carcinosarcomas were reclassified by World Health Organization as high-grade uterine carcinomas in 2014. Due to its rare histology, comprising only 5% of uterine carcinomas, there is a small representation of this tumor in studies that evaluate metastatic uterine carcinomas treatment. In 2022, the treatment of metastatic uterine carcinomas has...
ABSTRACT Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events. Material and Methods: In this retrospective study, we analyzed a cohort of patients with metastatic solid tumors treated at an oncology reference center with at least one dose of...
ABSTRACT Immunotherapy (IT) in the form of monoclonal antibodies targeting coreceptors involved in the modulation of the immune synapse represents a standard of care for patients with distinct malignancies. Over the past years, evidences supporting the clinical use of IT both in monotherapy, as well as in combinatorial regimens, grew...
The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring mutations: a systematic review and meta-analysis BRAF
ABSTRACT Objectives: Immune-checkpoint inhibitors (ICI) and targeted-therapies (TT) have become standard options for BRAF-V600 metastatic melanomas (MM). Recently, randomized trials (RCT) addressed the efficacy of combined approaches, with conflicting results. We sought to evaluate efficacy and safety of first-line combination ICI and BRAF/MEK inhibitors (triplets) versus BRAF/MEKi (doublets). Methods: We performed a...
ABSTRACT The objective of this study was to identify the available evidence on the parameters that should be considered to improve the quality and safety of the prescription of systemic antineoplastic treatment. This is an integrative review carried out in the EMBASE, LILACS, and PubMed databases, from 2015 to 2019....
ABSTRACT Targeted and immunotherapy have revolutionized cancer treatment. They safely substitute for traditional chemotherapy in a significant and growing number of malignancies. In this article, we review the United States Food and Drug Administration (FDA) - approved targeted and immunotherapies, currently used in oncology and compare their safety and efficacy...
ABSTRACT Merkel cell carcinomas are rare cutaneous malignancies with neuroendocrine features that affect elderly individuals with a history of chronic sun exposure and immunosuppression. More recently, a human viral pathogen, the Merkel cell polyomavirus, has been implicated in the carcinogenesis of this disease. Its particularly aggressive biological behavior, the delay...
